Further studies are warranted to elucidate the mechanism of action for tumor growth inhibition in FGFR1-overexpressing HCC PDX models, and to confirm the genomic correlation of the drug sensitivity with overexpression of FGFR1 gene. This evidence concerns the gene FGFR1 and neoplasm.